Skip to main content
Clinical Trials/NCT07575230
NCT07575230Enrolling By InvitationPhase 4

Non-Opioid Pain Management After Mohs Reconstruction: An Investigator-Initiated, Prospective, Randomized Clinical Trial of Suzetrigine vs Hydrocodone/Acetaminophen

Baylor Research Institute1 site in 1 country75 target enrollmentStarted: November 3, 2025Last updated:

Trial Snapshot

Phase
Phase 4
Status
Enrolling By Invitation
Enrollment
75
Locations
1

Study Overview

Brief Summary

To compare suzetrigine versus hydrocodone/acetaminophen for postoperative pain control following dermatologic surgery.

Detailed Description

This study is a randomized, controlled trial that is evaluating the safety and efficacy of suzetrigine as a postoperative pain medication compared to the standard of care Hydrocodone/Acetaminophen in patients undergoing Mohs micrographic surgery (MMS) who are at high-risk for postoperative pain and opioid use. The goal is to reduce opioid prescription use and give patients a non-opioid pain medication option for particularly painful surgeries. Patients will be randomized into one of two groups, one group will receive the interventional medication and the other the standard of care medication.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 89 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • adults between the age of 18-89
  • individuals who have a cutaneous tumor treated by MMS

Exclusion Criteria

  • individuals younger than 18 and older than 89
  • individuals taking medications that interact with the CYP3A (Cytochrome P450 3A) pathway
  • individuals with liver disease

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials